Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Sanofi India Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 199210-02-2015
Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Sanofi India Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Reliance Capital Asset Management Ltd has submitted the disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Resignation of Director
Sanofi India Ltd has informed BSE that Mr. A. Ortoli, who was Senior Vice President, Intercontinental, Global Operations of Sanofi SA, France (the Companys ultimate holding Company) has resigned as a Director of the Company with effect from January 21, 2015 following his retirement from the Sanofi Group.FY14 results on Feb 20, 2015
Sanofi India Ltd has informed BSE that a Meeting of the Board of Directors of the Company will be held on February 20, 2015 for approving the audited Accounts for the year ended December 31, 2014 and also to consider recommendation of final Dividend for the said financial year.Shareholding Pattern For December 31, 2014
Sanofi India Ltd has informed BSE about the Shareholding Pattern as on December 31, 2014.Sale of five floors owned by the Company in Hoechst House, Nariman Point, Mumbai
Sanofi India Ltd has informed BSE that the Board of Directors of the Company has approved of the Company selling its commercial premises, being five floors and corresponding car-parking spaces in the building known as Hoechst House situated at Nariman Point, Mumbai to Bright Star Investments Private Limited and its Group companies for a total consideration of Rs. 1342.56 million....Limited Review Report for Sept 30, 2014
Sanofi India Ltd has submitted to BSE a copy of the Limited Review Report for the period ended September 30, 2014.Announces Q3 results
Sanofi India Ltd has announced the following Unaudited Standalone results for the quarter ended September 30, 2014:The Company has posted a net profit after exceptional items of Rs. 620 million for the quarter ended September 30, 2014 as compared to Rs. 769 million for the quarter ended September 30, 2013. Total Income has increased from Rs. 5127 million for the quarter ended September 30, 2013 to Rs. 5290 million for the quarter ended September 30, 2014.Shareholding Pattern For September 30, 2014
Sanofi India Ltd has informed BSE about the Shareholding Pattern as on September 30, 2014.Q3 results on Nov 11, 2014
Sanofi India Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 11, 2014 for approving the Unaudited Financial Results for the quarter and nine months ended September 30, 2014 (Q3).